Atogepant
3 NDCs across 1 manufacturer|0 Generic,3 Brand
Atogepant is used to treat migraine disorders, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Sep 28, 2021. In 2024, Medicare Part D spent $260 million on Atogepant across 210,000 claims for 45,000 beneficiaries.
Atogepant is available as 3 NDCs from 1 manufacturer (0 generic, 3 brand), with NADAC prices from $38.36 to $38.45 per EA — a 0% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
3
0G / 3B
Manufacturers
1
competing in market
Price Spread
$38.36 – $38.45
per EA
7d Activity
avg -0.1% WoW · of 3 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
AbbVie Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Calcitonin Gene-related Peptide Receptor Antagonist class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing ATOGEPANT
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
QULIPTA 60 MG TABLET | $38.4494 per EA | -0.01% |
QULIPTA 30 MG TABLET | $38.3777 per EA | -0.04% |
QULIPTA 10 MG TABLET | $38.3583 per EA | -0.18% |
Frequently Asked Questions
What is Atogepant used to treat?
Atogepant is used to treat migraine disorders, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Atogepant?
In 2024, Medicare Part D spent $260 million on Atogepant across 210,000 claims for 45,000 beneficiaries.
How many Atogepant products are on the market?
The Atogepant drug market contains 3 NDCs from 1 manufacturer — 0 generic and 3 brand products.
What is the price range for Atogepant?
NADAC reference prices for Atogepant range from $38.3583 to $38.4494 per EA — a 0% difference between cheapest and most expensive.
Which manufacturers make Atogepant?
1 manufacturer lists Atogepant in NADAC. Ranked by number of NDCs, the largest are AbbVie Inc. (3).
How has the price of Atogepant changed recently?
Over the past 7 days, 0 Atogepant NDCs rose and 3 fell, with a market-wide average change of -0.1%.